Name of journal: *World Journal of Clinical Oncology*

ESPS Manuscript NO: 8245

Columns: TOPIC HIGHLIGHT

WJCO 5th Anniversary Special Issues (2): Breast cancer

**Caring for the breast cancer survivor’s health and well-being**

Casey MP *et al.* Caring for the breast cancer survivor

Petra M Casey, Stephanie S Faubion, Kathy L MacLaughlin, Margaret E Long, Sandhya Pruthi

**Petra M Casey, Margaret E Long,** Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905, United States

**Stephanie S Faubion,** Women’s Health Clinic, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, United States

**Kathy L MacLaughlin,** Department of Family Medicine, Mayo Clinic, Rochester, MN 55905, United States

**Sandhya Pruthi,** Department of Internal Medicine and Breast Clinic, Mayo Clinic, Rochester, MN 55905, United States

**Author contributions:** All authors contributed substantially to the conception and design of the article, acquisition of data, analysis, and interpretation of data; drafting and critical revision of the article for important intellectual content; and final approval of the submitted version.

**Supported by** The research grant support from Merck and certified Nexplanon

**Correspondence to: Petra M Casey, MD, Associate Professor, OBGYN,** Department of Obstetrics and Gynecology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States. casey.petra@mayo.edu

**Telephone:** +1-507-2668680 **Fax:** +1-507-2667953

**Received:** December 21, 2014 **Revised:** April 25, 2014

**Accepted:** June 10, 2014

**Published online:**

**Abstract**

The breast cancer care continuum entails detection, diagnosis, treatment, and survivorship. During this time, focus on the whole woman and medical concerns beyond the breast cancer diagnosis itself is essential. In this comprehensive review, we critically review and evaluate recent evidence regarding several topics pertinent to and specific for the woman living with a prior history of breast cancer. More specifically, we discuss the most recent recommendations for contraceptive options including long-acting reversible contraception and emergency contraception, fertility and pregnancy considerations during and after breast cancer treatment, management of menopausal vasomotors symptoms and vulvo-vaginal atrophy which often occurs even in young women during treatment for breast cancer. The need to directly query the patient about these concerns is emphasized. Our focus is on non-systemic hormones and non-hormonal options. Our holistic approach to the care of the breast cancer survivor includes such preventive health issues as sexual and bone health,which are important in optimizing quality of life. We also discuss strategies for breast cancer recurrence surveillance in the setting of a prior breast cancer diagnosis. This review is intended for primary care practitioners as well as specialists caring for female breast cancer survivors and includes key points for evidence-based best practice recommendations.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Breast cancer; Contraception; Vasomotor symptoms; Vulvovaginal atrophy; Sexual health; Osteopenia; Osteoporosis; Breast cancer recurrence; Breast cancer surveillance

**Core tip:** Caring for women with breast cancer at the time of diagnosis, during, and after treatment goes well beyond addressing the breast cancer alone. Holistic care includes safe, effective and convenient contraceptive options;local progestin intrauterine contraception may present an option for some breast cancer survivors. Discussion regarding the effects of chemotherapy on future fertility and pregnancy is an important part of survivorship care for women in child-bearing years. Addressing the effects of breast cancer treatment including vasomotor symptoms, vulvovaginal atrophy and sexual well-being is vital for all breast cancer survivors, butespecially important in the setting of adjuvant therapy with aromatase inhibitors.

Casey PM, Faubion SS, MacLaughlin KL, Long ME, Pruthi S. Caring for the breast cancer survivor’s health and well-being. *World J Clin Oncol* 2014; In press

**INTRODUCTION**

Breast cancer is the most common cancer diagnosis in women, and one in eight women will be diagnosed with breast cancer during her lifetime[[1](#_ENREF_1)]. Treatment, both surgical and chemotherapeutic, has evolved from the Halsted radical mastectomy to less invasive surgical techniques, combination treatment with focused radiation, and more effective adjuvant therapeutic options including tamoxifen and aromatase inhibitors (AIs)[[2](#_ENREF_2)]. These advances in early detection and effective therapies have led to a growing number of cancer survivors worldwide. As vital as these interventions are for a woman’s ultimate survival, the overall quality of life of a woman with breast cancer encompasses additional issues to be addressed by the health care provider caring for her during and after the diagnosis and treatment. These issues are often only elicited with compassionate, yet direct inquiry. Adequately addressing these concerns may ultimately make a significant difference in the general health, adherence to recommended therapy, and overall well-being of the woman and her loved ones. In this review, we focus on issues of contraceptive options, fertility and pregnancy after breast cancer treatment, management of bothersome vasomotor symptoms (VMS), vulvovaginal atrophy (VVA) and other sexual health issues, prevention of bone loss, and evidence-supported surveillance for breast cancer recurrence. Ideally, coordination of care with specialists in oncology, reproductive endocrinology, women’s health, breast health, gynecology, and primary care to address psychological and medical needs can provide a sense of a “medical home” extending beyond a woman’s cancer diagnosis, and can contribute to her overall quality of life.

**SURVEILLANCE AFTER BREAST CANCER**

Breast cancer survival has been attributed to advances in screening mammography and adjuvant therapy. In the United States, this survival benefit has led to a growing population of women who are living with a history of breast cancer[[3](#_ENREF_3)]. With the new focus on patient centeredness, a multidisciplinary approach is the expectation for survivorship care in order to best address the woman’s needs. A survey study demonstrated that breast cancer survivors reported a high rate of distress, neuropathy, chest wall, and arm pain. The majority of survivors stated that their medical needs were met, but only 49% reported that their psychological and spiritual needs were met following completion of cancer treatment[[4](#_ENREF_4)]. Surveillance to monitor for recurrence, management of treatment related adverse effects, and promotion of preventive and general health care are all integral components of improving quality of care of breast cancer survivors. The Institute of Medicine published a report in 2005, “From Cancer Patient to Cancer Survivor: Lost in Transition,” which was instrumental in promoting awareness of the importance of standardization of survivorship care, development of cancer treatment plans, and improvement in the quality of care of breast cancer survivors[[5](#_ENREF_5)].

The American Society of Clinical Oncology (ASCO) has outlined evidence-based recommendations for survivorship care[[6](#_ENREF_6)]. A study comparing intensive versus standard surveillance for early-stage breast cancer demonstrated no difference in the disease-free or overall survival[[7](#_ENREF_7)]. Recommendations for follow-up care after breast cancer include taking a history of symptoms and performing a physical examination every 3-6 mo for 3 years, then every 6-12 mo for 2 years, and then annually. Women are encouraged to perform monthly breast awareness and promptly report new findings to their health care provider. Breast imaging includes an annual mammogram for women with remaining breast tissue. Routine laboratory testing and radiologic studies are not recommended. Preventive health and screening guidelines for other cancers should follow average-risk recommendations. Women are advised to maintain a healthy lifestyle with regular exercise, avoidance of alcohol, and maintenance of healthy weight[[8](#_ENREF_8)]. Those with a hereditary predisposition for breast cancer or those with a known breast cancer mutation are advised to have an annual breast MRI in conjunction with mammography[[9](#_ENREF_9)].

# Adjuvant hormonal therapy has been shown to decrease breast cancer recurrence for hormone-dependent breast cancer[[10](#_ENREF_10)]. Both AIs and tamoxifen are typically prescribed for 5 years for estrogen receptor-positive breast cancer. There is further evidence that longer therapy is beneficial for estrogen receptor-positive disease. A recent large study, the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, comparing 5 *vs* 10 years of tamoxifen demonstrated a further reduction in recurrence and mortality after 10 years of tamoxifen in women with early-stage estrogen receptor-positive breast cancer[[11](#_ENREF_11)].

However, common side effects of antiestrogen therapies such as exacerbation of VMS, vaginal dryness, vaginal bleeding or spotting, and arthralgias can negatively impact quality of life for many women. These adverse effects can result in early discontinuation and nonadherence to adjuvant hormonal therapy[[12](#_ENREF_12)]. Clinicians can be proactive in assessing and counseling patients experiencing medication-related side effects. Various management options are available to provide relief of bothersome symptoms and evaluation of worrisome findings, such as postmenopausal bleeding in the setting of tamoxifen therapy, and can improve therapy adherence and survival.

**MANAGEMENT OF VASOMOTOR SYMPTOMS**

Vasomotor symptoms are among the most common bothersome symptoms associated with the menopausal transition, occurring in up to 80% of women[[13](#_ENREF_13)]. Though the experience of VMS varies, recent evidence suggests that VMS begin before the final menstrual period and may last for over a decade[[14](#_ENREF_14)]. Further, up to 10% of women in a Scandinavian study continued to experience VMS well into their 70s[[15](#_ENREF_15)]. Women undergoing treatment for breast cancer may also experience VMS as a consequence of therapy, specifically tamoxifen or AIs[[16](#_ENREF_16)].

Hormone therapy (HT) whether estrogen alone, estrogen plus progestin, or progestin alone effectively treats VMS[[17](#_ENREF_17),[18](#_ENREF_18)]. However, systemic hormone therapy has been associated with an increased recurrence risk in breast cancer survivors in some but not all studies[[19](#_ENREF_19),[20](#_ENREF_20)]. In a review of 15 studies between 1967 and 2001 by Batur *et al*[[21](#_ENREF_21)], menopausal HT (estrogen plus progestin in 14 of the 15) was not associated with increased cancer recurrence, cancer-related mortality, or total mortality. Nonetheless, synthetic progestins demonstrate proliferative effects in the breast and may augment carcinogenesis by stimulating conversion of differentiated cancer cells to cancer stem cells[[22](#_ENREF_22)]. In addition, the 13-year follow-up of the Women’s Health Initiative showed increased risk of breast cancer after approximately 5 years of therapy in the estrogen plus progestin group and not in the estrogen alone group, adding to the concern that certain progestins may increase breast cancer risk[[22](#_ENREF_22),[23](#_ENREF_23)]. There is no current data to support differential management of VMS for women with different receptor-positive tumor types (*i.e.*, ER, PR, and HER2neu).

In short, women on HT diagnosed with breast cancer need to discontinue therapy. There is no evidence-based guidance as to whether a taper is preferable to abrupt discontinuation, though a slow taper may be preferable based on expert opinion[[24](#_ENREF_24)]. Approximately 50% of women who discontinue HT will experience recurrence of VMS[[25](#_ENREF_25)].

**NONHORMONAL TREATMENT OPTIONS FOR VASOMOTOR SYMPTOMS**

Given the safety concerns with HT use in breast cancer survivors, nonhormonal treatments are often considered[[26](#_ENREF_26)]. Lifestyle modifications for management of VMS are recommended as first-line interventions. They include avoidance of triggers (caffeine, alcohol, tobacco, warm beverages, spicy foods), dressing in layers, and the use of cooling or wicking clothing and bed linen. The results of studies regarding soy, exercise, and acupuncture have been mixed,[[27-29](#_ENREF_27)] whereas paced respirations may be of some benefit for VMS management[[30](#_ENREF_30),[31](#_ENREF_31)]. Caution should be exercised with nonprescription products claiming efficacy for VMS, as robust scientific evidence is lacking. Further, these products are not regulated by the Food and Drug Administration (FDA) raising questions about safety.

A 2010 Cochrane review of 16 randomized controlled trials of nonhormonal interventions for VMS management in breast cancer survivors showed a mild-to-moderate effect with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentin, clonidine, and relaxation therapy[[32](#_ENREF_32)]. Limitations of existing studies include significant placebo effect, differing measures of efficacy, and in many, short duration of treatment. Areas of uncertainty are potential long-term drug effects, optimal duration of therapy, and symptom recurrence upon discontinuation[[31](#_ENREF_31)].

Gabapentin has been shown to reduce VMS in breast cancer survivors[[33](#_ENREF_33),[34](#_ENREF_34)]. However, extended-release gabapentin did not meet FDA approval for this indication in 2013, due to concerns regarding marginal effectiveness and adverse effects such as dizziness.

Low-dose mesylate salt of paroxetine (Brisdelle 7.5 mg) modestly reduces VMS frequency in clinical trials and is the first FDA-approved nonhormonal option for VMS management[[35](#_ENREF_35)]. In a recent year-long randomized, double-blind, placebo-controlled trial, desvenlafaxine (Pristiq) was found to be associated with a statistically significant and clinically meaningful VMS reduction[[36](#_ENREF_36)]. However, desvenlafaxine did not receive FDA approval for this indication in 2011 due to concerns regarding the risk-benefit profile.

Sexual side effects of antidepressants, including difficulty with arousal and orgasm, are associated with many antidepressants with some exceptions (bupropion and mirtazapine)[[37](#_ENREF_37)]. In fact, bupropion has been used in the setting of sexual side effects associated with other antidepressants, though it has not been studied specifically in women with breast cancer[[38](#_ENREF_38)].

In breast cancer patients, an interaction between tamoxifen and SSRIs that strongly inhibit cytochrome P450 2D6 (CYP2D6) may exist, potentially reducing endoxifen, the bioactive form of tamoxifen. Newer evidence is concerning for a potential correlation between tamoxifen efficacy or risk of breast cancer recurrence with an inherited variant of the CYP2D6 allele or with the use of medications which may inhibit the CYP2D6 enzyme[[39](#_ENREF_39)]. Therefore, caution is currently advised when using strong inhibitors of CYP2D6 in breast cancer patients on tamoxifen.

Though some data suggest short-term improvement in VMS with stellate ganglion block in breast cancer survivors, results have been mixed and further investigation is needed[[40](#_ENREF_40),[41](#_ENREF_41)].

Providers may choose a VMS management option based on potential side effects, medical comorbidities, and patient preference. For example, if a patient suffers from migraine, gabapentin may be reasonable. If a mood disorder is present, an antidepressant may be most appropriate.

**SEXUAL HEALTH CONCERNS IN THE BREAST CANCER SURVIVOR**

While sexual health is increasingly identified as an important issue in cancer survivors, providers don’t always query patients about sexual function, and patients are often reluctant to bring up concerns, fearing nothing can be done or dissuaded by provider discomfort[[42](#_ENREF_42)]. Most patients are, however, interested in discussing sexual function and want their providers to broach the topic. Survivors of breast cancer face well-described sexual health challenges, including changes in body image, loss of fertility, impairment of relationships, lack of libido, VVA, and dyspareunia. Both the experience of cancer and its treatment can have a significant impact on sexual functioning. Chemotherapy-induced ovarian insufficiency (or risk-reducing oophorectomy) as well as medications used to treat or control disease may result in hormonal loss or blockade, potentially leading to changes in libido, VVA, dyspareunia, and decreased quality of life[[43](#_ENREF_43)].

**MANAGEMENT OF VULVOVAGINAL ATROPHY IN THE BREAST CANCER SURVIVOR**

In contrast with VMS, which tend to improve with time, symptoms associated with VVA progress over time. In women with VVA, meticulous vulvar care is important, and products with perfumes or dyes should be avoided (toilet tissue, soaps, fabric softeners, stimulating lubricants, vaginal hygiene products)[[44](#_ENREF_44)]. Vaginal moisturizers can be used on a regular basis to replace vaginal moisture, whereas lubricants are needed with sexual activity to reduce friction[[45](#_ENREF_45)]. First-line therapies for VVA include not only vaginal moisturizers and lubricants, but also regular sexual activity (with partner, device, or solo) to stimulate blood flow to the area. Though data is lacking, expert opinion favors proactively educating postmenopausal women about vulvovaginal health in order to preserve sexual function[[46](#_ENREF_46)]. This concept is perhaps even more pertinent for the breast cancer survivor. Pelvic floor physical therapy may be utilized to facilitate pelvic floor relaxation, and may include education, relaxation techniques of the pelvic floor muscles, deep breathing, biofeedback, and instruction on the use of lubricated vaginal dilators in graduated sizes to gently stretch vaginal tissues[[47](#_ENREF_47)]. Psychosocial interventions, including individual or couple counseling, cognitive behavioral therapy, and mindfulness-based interventions are utilized in breast cancer survivors to improve coping strategies. These also serve to address a number of concerns that impact sexuality including altered body image, anxiety, fear of recurrent disease, changes in relationships, and dyspareunia, though supportive evidence is sparse[[43](#_ENREF_43)].

In particular, breast cancer survivors on AI therapy experience profound estrogen deprivation, vaginal dryness, and dyspareunia[[48](#_ENREF_48)]. A few small studies have demonstrated significant increases in plasma estradiol concentrations in postmenopausal breast cancer patients on AIs treated with local vaginal estrogen therapy (LVET). However, no studies to date have revealed an increased risk of breast cancer recurrence with LVET use[[49](#_ENREF_49)]. It is becoming increasingly evident that severe VVA can have a negative impact on quality of life and may result in medication noncompliance. LVET for severe symptoms is available in ring, cream, or tablet form, but the long-term safety and systemic absorption from these various preparations are still largely unknown. Newer evidence has demonstrated that serum pharmacokinetics can be used to determine the maximum annual dose delivered and serum estradiol levels of various LVETs. Vaginal estrogen tablets (10 ug) prescribed twice a week demonstrated the lowest annual delivered systemic dose as compared to other LVET[[44](#_ENREF_44)]. Providers should be aware of barriers to breast cancer treatment adherence and take into account individual patient’s symptom severity, preference, and potential cancer recurrence risk when considering LVET.

A trial utilizing topical testosterone vaginal cream in 20 breast cancer patients on AIs revealed improvements in vaginal dryness, dyspareunia, and vaginal maturation index (VMI) without a change in estradiol levels. The significance of increased reported testosterone levels is unclear[[50](#_ENREF_50)]. Likewise, intravaginal dehydroepiandrosterone (DHEA) has been associated with improvements in bothersome vaginal symptoms, VMI, and vaginal pH without significant changes in serum estrogen or androgen levels[[51](#_ENREF_51)]. A trial of vaginal DHEA in 465 breast cancer survivors with VVA is underway, with results expected in 2014[[52](#_ENREF_52)].

Ospemifene is a selective estrogen receptor modulator (SERM) FDA-approved for treatment of moderate-to-severe dyspareunia. While it has demonstrated antiestrogenic effects in preclinical models of breast cancer, it has not been studied in breast cancer survivors and is not approved for use in this population or in those at high risk of breast cancer[[53](#_ENREF_53)].

**FERTILITY AFTER BREAST CANCER**

While many women are diagnosed with breast cancer after menopause, a 20-year-old woman in the United States has about a 0.5% chance of developing breast cancer in her reproductive years, bringing up the impact of cancer therapy on future fertility, and of pregnancy on cancer recurrence[[54](#_ENREF_54)]. In general, the impact of chemotherapy on fertility is related to age-related baseline fertility as well as the type and dose of chemotherapy used[[55](#_ENREF_55),[56](#_ENREF_56)]. In women who desire pregnancy after breast cancer, fertility preservation should be discussed at the time of diagnosis. While a full discussion is beyond the scope of this review, both embryo and oocyte cryopreservation are considered standard options. With cycle-day-independent ovarian stimulation protocols, the timing of cancer therapy initiation can be minimally affected. In order to reduce potential risks associated with increased estrogen levels at ovarian stimulation, many regimens now utilize letrozole. Gonadotropin-releasing hormone analogs should not be used for fertility preservation due to unproven efficacy[[57](#_ENREF_57)].

While women were previously counseled to wait two years prior to conceiving after breast cancer diagnosis, newer published data does not demonstrate an alteration in survival with breast cancer to pregnancy intervals longer than 10 mo[[58](#_ENREF_58)]. Estrogen-receptor status does not impact breast cancer recurrence with pregnancy[[59](#_ENREF_59)]. Initial studies noting improved outcome in women who become pregnant after breast cancer were attributed to better baseline status in women who chose pregnancy, the so-called “healthy mother effect”[[60](#_ENREF_60)]. A meta-analysis designed to correct for the “healthy mother effect” included over 1000 women with pregnancy after breast cancer diagnosis and over 13000 health-matched controls. This study noted improved survival in women who became pregnant after breast cancer treatment as compared to those who did not, hazard ratio 0.51 [95% confidence interval (CI), 0.42-0.62] suggesting that pregnancy at least 10 mo post breast cancer treatment in women < 45 years does not adversely affect prognosis and may in fact significantly improve survival[[60](#_ENREF_60)].

About 50% of women can lactate after breast cancer therapy, but breast milk volume tends to be reduced[[61](#_ENREF_61)].

**ASSOCIATION BETWEEN HORMONAL CONTRACEPTION AND BREAST CANCER**

Though data is difficult to interpret given varying hormonal doses and lengths of follow-up, there is no clear evidence that hormonal contraceptive use (oral contraceptive have been most thoroughly studied), past or present, is associated with a significantly increased breast cancer risk[[62](#_ENREF_62)]. Importantly, older studies reporting a weak association contain data pertaining to older, higher dose contraceptive formulations not in use today[[63](#_ENREF_63),[64](#_ENREF_64)]. Therefore, patients can be reassured of the unlikely contribution of prior hormonal contraception to the breast cancer diagnosis.

**CONTRACEPTION OPTIONS DURING BREAST CANCER TREATMENT AND BEYOND**

Safe, effective, and convenient contraception should be discussed and made available to all women undergoing diagnosis, treatment, and surveillance for breast cancer. Women not wishing further fertility may consider male or female sterilization with inherent failure rates < 1%[[65](#_ENREF_65),[66](#_ENREF_66)]. A number of minimally invasive options for sterilization now exist including laparoscopic tubal ligation and hysteroscopic sterilization (Essure). It is important to note that the latter does not have immediate efficacy, and tubal occlusion must be confirmed by hysterosalpingogram 12 wk following the procedure[[67](#_ENREF_67)]. Therefore, as with male sterilization, another form of contraception should be used until efficacy can be assured[[65](#_ENREF_65),[67](#_ENREF_67)].

During the evaluation for breast cancer, a woman on hormonal contraception, including combined hormonal contraception, should continue using this method until she receives appropriate counseling regarding future reproductive goals, an assessment of medical needs beyond the breast cancer, and, most importantly, until a new method is initiated. The United States Medical Eligibility Criteria for Contraceptive Use (US MEC) considers all hormonal contraception as “advantages generally outweigh theoretical or proven risks” in the setting of an undiagnosed breast mass[[68](#_ENREF_68)]. Nonhormonal methods including the copper T380 (CuIUD or ParaGard) and barrier methods have “no restriction in use” in this setting. However, even with perfect use, barrier method alone is unlikely to provide sufficient efficacy and convenience to most women, given its 15% failure rate[[69](#_ENREF_69)]. An unplanned pregnancy at a time when breast cancer treatment should be initiated can lead to needlessly difficult choices about pregnancy termination or treatment delay.

The Cu-IUD is the only hormone-free, long-acting reversible contraceptive (LARC) currently available in the United States and has “no restrictions for use” in the setting of current breast cancer[[68](#_ENREF_68)]. Pregnancy rates are < 1% per year with this method indicated for up to 10 years[[70](#_ENREF_70)]. In addition, a Cu-IUD can be placed at any time that pregnancy can be reasonably ruled out, as well as within 5 d of unprotected intercourse if emergency contraception is desired. Additional back-up contraception is not required after insertion. Further, due to its non-systemic mechanism of action, chemotherapy-associated nausea and vomiting does not alter efficacy.

While the Cu-IUD represents the first-line reversible contraception in women with breast cancer, concurrent medical issues such as endometrial proliferation on tamoxifen, anemia, menorrhagia, and dysmenorrhea may warrant consideration of local progestin therapy, especially in women with hormone receptor-negative tumor types. These considerations need to be balanced with US MEC rating of “unacceptable health risks, method not to be used” for all hormone-containing contraceptives. The newer 13.5 mg levonorgestrel releasing system (low dose LNG-IUS) (Skyla) has lower circulating levels than the 52 mg LNG-IUS (Mirena) used in prior studies of LNG-IUS and breast cancer[[71-74](#_ENREF_71)]. In addition to being an extremely effective reversible contraception that is effective for up to 3 years, low dose LNG-IUS may improve anemia, menorrhagia, and dysmenorrhea that can be associated with Cu-IUD, while exposing a woman to lower circulating levels of levonorgestrel than LNG-IUS (Mirena). However, there is currently no evidence regarding low dose LNG-IUS efficacy for menorrhagia treatment or its safety in the setting of breast cancer.

A small case-control study of women using LNG-IUS compared 79 women, who started or continued using LNG-IUS after diagnosis of breast cancer, and 120 controls. While there was no increased risk of recurrence overall, there was concern about the 3.39 adjusted hazard ratio of breast cancer recurrence (95%CI, 1.01-11.35) in a subgroup who developed breast cancer while using LNG-IUS and continued its use[[74](#_ENREF_74)]. This finding contrasts with population data that has not found an increased risk of breast cancer in LNG-IUS users as compared to Cu-IUD users in 5100 breast cancer patients and 20000 controls[[73](#_ENREF_73)].

LNG-IUS is indicated for the treatment of menorrhagia and can decrease menstrual blood loss by up to 90%[[75](#_ENREF_75)]. This is compared with a 40% reduction in menstrual blood loss with antifibrinolytics and about 25% with NSAIDs[[76](#_ENREF_76),[77](#_ENREF_77)]. Unfortunately, there is virtually no data on the contraceptive implant (Implanon, Nexplanon) in the setting of breast cancer[[78](#_ENREF_78)]. As with all other hormonal LARC methods, the US MEC rates the implant as “unacceptable health risk, method should not be used” with current breast cancer and as “theoretical or proven risks usually outweigh the advantages” after 5 years without breast cancer recurrence[[68](#_ENREF_68)].

When determining the need for contraception after breast cancer diagnosis, amenorrhea and elevated gonadotropins such as follicular stimulating hormone (FSH) are unreliable markers of infertility in women who have received chemotherapy[[55](#_ENREF_55),[79](#_ENREF_79)]. The incidence of chemotherapy-induced amenorrhea is reported to be 53%-89%, and is more likely to be reversible in women under 40 years than older women[[80](#_ENREF_80)].

**EMERGENCY CONTRACEPTION**

The World Health Organization (WHO) has determined that there is no medical condition wherein the risks of emergency contraception outweigh its benefits[[81](#_ENREF_81)].Therefore emergency contraception should be available to women diagnosed with and undergoing treatment for breast cancer.

The Cu-IUD can serve as 96% effective emergency contraception if inserted within 5 d post-unprotected intercourse, and can remain as primary hormone-free, yet reversible contraception for up to 10 years. In one study, over 80% of women who received Cu-IUD for emergency contraception continued using it for primary contraception thereafter[[82](#_ENREF_82)].

Additional emergency contraception methods include levonorgestrel (LNG or PlanB one step) and Ulipristal (UPA or Ella)[[83](#_ENREF_83),[84](#_ENREF_84)]. Plan B is now available in the United States without a prescription regardless of patient age, and is indicated for use within 72 h of unprotected intercourse[[84](#_ENREF_84)]. An efficacy rate of 85% has been reported. LNG alone is more effective than the combined Yuzpe regimen of oral contraceptives and is associated with fewer side-effects[[85](#_ENREF_85)]. UPA is indicated in a single dose for emergency contraception up to 5 d post-unprotected intercourse[[83](#_ENREF_83)]. Lower failure rates than LNG have been reported with UPA, (OR, 0.35, 0.58, 0.55 at 24, 72, and 120 h respectively)[[86](#_ENREF_86)]. Differences in efficacy of emergency contraception have been reported in women with normal versus elevated body mass index (BMI). As compared to women with a BMI < 25 kg/m2, women with a BMI of 25-29 kg/m2 had a 1.5-fold increased risk of pregnancy whereas those with a BMI > 30 kg/m2 had a 3.6-fold increased risk with LNG EC versus UPA[[86](#_ENREF_86)]. Therefore, UPA or Cu-IUD, which do not have BMI-related efficacy differences, should be considered over LNG in women with elevated BMI.

**BONE HEALTH**

Bone health has been increasingly recognized as a significant issue for breast cancer survivors from the standpoint of osteoporosis prevention as well as its diagnosis and treatment[[87-89](#_ENREF_87)]. A recently published survey study found that women aged 65 and older with a breast cancer diagnosis had a higher prevalence of osteoporosis and falls. However, their risk was not more likely to have been identified by their health care provider, and bone health or fall prevention discussed[[90](#_ENREF_90)].

There are multiple mechanisms by which breast cancer treatment impacts bone health. Primary ovarian insufficiency or premature menopause often results from treatment with gonadotropin-releasing hormone agonists or chemotherapeutic agents in previously premenopausal women and increases risk of osteoporosis[[88](#_ENREF_88)]. The use of antiestrogen therapies can cause estrogen deficiency resulting in bone loss and reduced bone integrity[[91](#_ENREF_91)]. Tamoxifen has different effects on bone in pre- versus postmenopausal women. In premenopausal women, tamoxifen has been shown to cause a 1%-2% bone loss over 1-2 years, but experts note that this is not a clinically significant change, and that monitoring or treatment solely based on tamoxifen use is not indicated. In contrast, tamoxifen is associated with increased bone density in postmenopausal women[[92](#_ENREF_92)]. Of greater concern for a negative impact on bone health and fracture risk is the use of AIs. AIs are used in postmenopausal women with hormone receptor-positive breast cancer to reduce recurrence risk with a demonstrated survival benefit[[93](#_ENREF_93),[94](#_ENREF_94)]. However, AIs result in substantial reduction in estrogen production and estradiol levels, and are associated with decreased bone mineral density (BMD) and higher rate of fracture[[95](#_ENREF_95)].

Strategies for prevention of bone loss in all women, including those receiving antiestrogen therapies, include counseling on the importance of adequate calcium (1200 mg per day) and vitamin D (800-1000 IU per day) through diet or supplement, regular exercise including both weight-bearing and muscle strengthening, advice on fall prevention, smoking cessation, and avoidance of excess alcohol[[96](#_ENREF_96)].

In 2003 the ASCO published an algorithm (Figure 1) for screening and treatment specifically for breast cancer patients that recommended BMD screening annually for all postmenopausal women on AIs and for premenopausal women with treatment-induced premature menopause, as well as for all breast cancer patients aged 65 years and older or those aged 60-64 years with risk factors. The treatment guideline at that time only called for bisphosphonate or raloxifene for women with a T-score of -2.5 or lower[[97](#_ENREF_97)]. A consensus statement from a UK Expert Group in 2008 divided that algorithm into specific guidelines for formerly premenopausal women with treatment-induced premature menopause (defined in the publication as < 45 years old) and for postmenopausal women treated with AIs (Figures 2 and 3). For women with continued menstruation or postmenopausal women older than 45 years old and either on tamoxifen or not on AIs, no specific recommendation is given for screening. Any woman with a T-score < -2.0 or with a history of vertebral fracture is advised to have evaluation for secondary causes of osteoporosis[[92](#_ENREF_92)].

For breast cancer patients with treatment-induced early menopause < 45 years old, a BMD measurement by spine and hip dual energy X-ray absorptiometry (DXA) is recommended. If a woman not on an AI had a T-score < -2.0, bisphosphonate treatment is recommended with a follow up DXA in 24 mo. With a score of -1.0 or higher, no further testing is indicated. If the T-score is between -1.0 and -2.5, a repeat DXA in 24 mo is advised. For the woman on AI, the threshold for treatment drops to a T-score of < -1.0 with repeat DXA recommended at 24 mo post bisphosphonate initiation. For a woman on AI and in premature menopause at < 45 years old, a T-score > -1.0 results in a recommendation for DXA in 24 mo[[92](#_ENREF_92)].

For postmenopausal women starting AI therapy, DXA of the spine and hip is recommended. If the T-score is < -2.0 or if the woman is 75 years or older with any osteoporosis risk factors, bisphosphonate is recommended with follow-up DXA in 24 mo. Similar to the algorithm for breast cancer patients with early menopause, a T-score of -1.0 or higher requires no further screening unless indicated by a change in the clinical situation. For a T-score between -1.0 and -2.5, a follow-up DXA in 24 mo is recommended[[92](#_ENREF_92)].

All breast cancer patients with known vertebral fractures should be considered for treatment per the UK Expert Group guidelines. Another indication for treatment is an annual bone loss rate of > 4% in both the premature menopause and postmenopausal AI-treated groups[[92](#_ENREF_92)].

**CONCLUSION**

In focusing on the woman undergoing treatment and surveillance for breast cancer, attention to a number of concurrent issues beyond the breast cancer itself will impact her satisfaction with treatment and overall care. Appropriate counseling and evidence-supported surveillance strategy along with age-appropriate testing will promote overall health and perhaps a sense of some control over her care. Careful attention to medication-related side effects including chemotherapy-induced VVA with resultant dyspareunia can certainly affect her well-being and relationship with her partner. The availability of nonhormonal treatment options for VVA and VMS can help her focus on her recovery. If future fertility is a concern, she should ideally be evaluated by a reproductive endocrinologist prior to initiation of chemotherapy and counseled regarding fertility preservation options. Pregnancy is generally not advised for at least 10 mo after breast cancer therapy, but advancing maternal age and other factors need to be considered in individual counseling. If contraception is desired, women should be counseled about both reversible and permanent hormone-free options, but they should not discontinue current contraception until the initiation of an alternate method. Chemotherapy-induced amenorrhea should not be considered permanent ovarian insufficiency, especially in women younger than 40 years. Likewise, elevated FSH in this setting is not an indicator of permanent ovarian insufficiency. Attention to bone health is important in breast cancer survivors, particularly in the context of chemotherapy-induced premature menopause or AI use. A multidisciplinary, comprehensive, and holistic approach to the woman with breast cancer can facilitate her transition from breast cancer patient to breast cancer survivor.

**REFERENCES**

1 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin* 2012; **62**: 10-29 [PMID: 22237781 DOI: 10.3322/caac.20138]

2 **Berry DA**, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Effect of screening and adjuvant therapy on mortality from breast cancer. *N Engl J Med* 2005; **353**: 1784-1792 [PMID: 16251534 DOI: 10.1056/NEJMoa050518]

3 **Siegel R**, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. *CA Cancer J Clin* 2012; **62**: 220-241 [PMID: 22700443 DOI: 10.3322/caac.21149]

4 **Thompson CA**, Stan DL, Solberg Nes L, Jenkins SM, Lackore KA, Pruthi S. Breast cancer survivors' self-reported needs and preferences of survivorship care. *Breast J* 2013; **20**: 107-109 [PMID: 24262015 DOI: 10.1111/tbj.12221]

5 **Hewitt M**, Greenfield S, Stovall E (Eds.): From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academics Press; 2006

6 **Loblaw DA**, Prestrud AA, Somerfield MR, Oliver TK, Brouwers MC, Nam RK, Lyman GH, Basch E. American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. *J Clin Oncol* 2012; **30**: 3136-3140 [PMID: 22778311 DOI: 10.1200/jco.2012.42.0489]

7 **Rosselli Del Turco M**, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. *JAMA* 1994; **271**: 1593-1597 [PMID: 7848404]

8 **Barnett GC**, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the incidence of breast cancer: do they affect survival from the disease? *J Clin Oncol* 2008; **26**: 3310-3316 [PMID: 18612147 DOI: 10.1200/jco.2006.10.3168]

9 **Saslow D**, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin* 2007; **57**: 75-89 [PMID: 17392385]

10 **Winer EP**, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. *J Clin Oncol* 2005; **23**: 619-629 [PMID: 15545664 DOI: 10.1200/jco.2005.09.121]

11 **Davies C**, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet* 2013; **381**: 805-816 [PMID: 23219286 DOI: 10.1016/s0140-6736(12)61963-1]

12 **Hershman DL**, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. *J Clin Oncol* 2010; **28**: 4120-4128 [PMID: 20585090 DOI: 10.1200/jco.2009.25.9655]

13 **Gold EB**, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, Sternfeld B, Matthews K. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. *Am J Public Health* 2006; **96**: 1226-1235 [PMID: 16735636 DOI: 10.2105/ajph.2005.066936]

14 **Freeman EW**, Sammel MD, Lin H, Liu Z, Gracia CR. Duration of menopausal hot flushes and associated risk factors. *Obstet Gynecol* 2011; **117**: 1095-1104 [PMID: 21508748 DOI: 10.1097/AOG.0b013e318214f0de]

15 **Rödström K**, Bengtsson C, Lissner L, Milsom I, Sundh V, Björkelund C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. *Menopause* 2002; **9**: 156-161 [PMID: 11973438]

16 **Files JA**, Ko MG, Pruthi S. Managing aromatase inhibitors in breast cancer survivors: not just for oncologists. *Mayo Clin Proc* 2010; **85**: 560-56; quiz 566 [PMID: 20511486 DOI: 10.4065/mcp.2010.0137]

17 **North American Menopause Society.** The 2012 hormone therapy position statement of: The North American Menopause Society. *Menopause* 2012; **19**: 257-271 [PMID: 22367731 DOI: 10.1097/gme.0b013e31824b970a]

18 **Prior JC**, Hitchcock CL. Progesterone for hot flush and night sweat treatment--effectiveness for severe vasomotor symptoms and lack of withdrawal rebound. *Gynecol Endocrinol* 2012; **28 Suppl 2**: 7-11 [PMID: 22849758 DOI: 10.3109/09513590.2012.705390]

19 **Holmberg L**, Anderson H. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. *Lancet* 2004; **363**: 453-455 [PMID: 14962527 DOI: 10.1016/s0140-6736(04)15493-7]

20 **Holmberg L**, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. *J Natl Cancer Inst* 2008; **100**: 475-482 [PMID: 18364505 DOI: 10.1093/jnci/djn058]

21 **Batur P**, Blixen CE, Moore HC, Thacker HL, Xu M. Menopausal hormone therapy (HT) in patients with breast cancer. *Maturitas* 2006; **53**: 123-132 [PMID: 16368466 DOI: 10.1016/j.maturitas.2005.03.004]

22 **Santen RJ**. Menopausal hormone therapy and breast cancer. *J Steroid Biochem Mol Biol* 2014; **142**: 52-61 [PMID: 23871991 DOI: 10.1016/j.jsbmb.2013.06.010]

23 **Manson JE**, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. *JAMA* 2013; **310**: 1353-1368 [PMID: 24084921 DOI: 10.1001/jama.2013.278040]

24 **Haskell SG**, Bean-Mayberry B, Gordon K. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms? *Menopause* 2009; **16**: 494-499 [PMID: 19182695 DOI: 10.1097/gme.0b013e31818fbff5]

25 **Ockene JK**, Barad DH, Cochrane BB, Larson JC, Gass M, Wassertheil-Smoller S, Manson JE, Barnabei VM, Lane DS, Brzyski RG, Rosal MC, Wylie-Rosett J, Hays J. Symptom experience after discontinuing use of estrogen plus progestin. *JAMA* 2005; **294**: 183-193 [PMID: 16014592 DOI: 10.1001/jama.294.2.183]

26 **de Villiers TJ**, Gass ML, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Global consensus statement on menopausal hormone therapy. *Climacteric* 2013; **16**: 203-204 [PMID: 23488524 DOI: 10.3109/13697137.2013.771520]

27 **Nelson HD**, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walker M, Humphrey L. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. *JAMA* 2006; **295**: 2057-2071 [PMID: 16670414 DOI: 10.1001/jama.295.17.2057]

28 **Sternfeld B**, Guthrie KA, Ensrud KE, LaCroix AZ, Larson JC, Dunn AL, Anderson GL, Seguin RA, Carpenter JS, Newton KM, Reed SD, Freeman EW, Cohen LS, Joffe H, Roberts M, Caan BJ. Efficacy of exercise for menopausal symptoms: a randomized controlled trial. *Menopause* 2014; **21**: 330-338 [PMID: 23899828 DOI: 10.1097/GME.0b013e31829e4089]

29 **Borud E**, White A. A review of acupuncture for menopausal problems. *Maturitas* 2010; **66**: 131-134 [PMID: 20060667 DOI: 10.1016/j.maturitas.2009.12.010]

30 **Hall E**, Frey BN, Soares CN. Non-hormonal treatment strategies for vasomotor symptoms: a critical review. *Drugs* 2011; **71**: 287-304 [PMID: 21319867 DOI: 10.2165/11585360-000000000-00000]

31 **Richardson MK**. Alternatives to hormone therapy for hot flashes: many choices but science is lacking. *Menopause* 2013; **20**: 980-982 [PMID: 23839221 DOI: 10.1097/GME.0b013e3182982436]

32 **Rada G**, Capurro D, Pantoja T, Corbalán J, Moreno G, Letelier LM, Vera C. Non-hormonal interventions for hot flushes in women with a history of breast cancer. *Cochrane Database Syst Rev* 2010: CD004923 [PMID: 20824841 DOI: 10.1002/14651858.CD004923.pub2]

33 **Pandya KJ**, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, Sweeney TJ, Banerjee TK, Flynn PJ. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. *Lancet* 2005; **366**: 818-824 [PMID: 16139656 DOI: 10.1016/s0140-6736(05)67215-7]

34 **Loprinzi CL**, Kugler JW, Barton DL, Dueck AC, Tschetter LK, Nelimark RA, Balcueva EP, Burger KN, Novotny PJ, Carlson MD, Duane SF, Corso SW, Johnson DB, Jaslowski AJ. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. *J Clin Oncol* 2007; **25**: 308-312 [PMID: 17146104 DOI: 10.1200/jco.2006.07.5390]

35 **Simon J.** Safety and Efficacy of Low-dose Mesylate Salt of Paroxetine (LDMP) for the Treatment of Vasomotor Symptoms; Abstract. In The North American Menopause Society 24th Annual Meeting. Dallas, TX; October 9-12, 2013

36 **Pinkerton JV**, Archer DF, Guico-Pabia CJ, Hwang E, Cheng RF. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. *Menopause* 2013; **20**: 38-46 [PMID: 23266839 DOI: 10.1097/GME.0b013e318274699f]

37 **Baldwin DS**, Palazzo MC, Masdrakis VG. Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. *Depress Res Treat* 2013; **2013**: 256841 [PMID: 23431429 DOI: 10.1155/2013/256841]

38 **Taylor MJ**, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. *Cochrane Database Syst Rev* 2013; **5**: CD003382 [PMID: 23728643 DOI: 10.1002/14651858.CD003382.pub3]

39 **Brauch H**, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. *J Clin Oncol* 2013; **31**: 176-180 [PMID: 23091108 DOI: 10.1200/jco.2012.44.6625]

40 **Haest K**, Kumar A, Van Calster B, Leunen K, Smeets A, Amant F, Berteloot P, Wildiers H, Paridaens R, Van Limbergen E, Weltens C, Janssen H, Peeters S, Menten J, Vergote I, Morlion B, Verhaeghe J, Christiaens MR, Neven P. Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up. *Ann Oncol* 2012; **23**: 1449-1454 [PMID: 22039079 DOI: 10.1093/annonc/mdr478]

41 **Guttuso T**. Stellate ganglion block for treating hot flashes: a viable treatment option or sham procedure? *Maturitas* 2013; **76**: 221-224 [PMID: 24021996 DOI: 10.1016/j.maturitas.2013.08.001]

42 **Mac Bride MB**, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. *Mayo Clin Proc* 2010; **85**: 87-94 [PMID: 20042564 DOI: 10.4065/mcp.2009.0413]

43 **Krychman ML**, Katz A. Breast cancer and sexuality: multi-modal treatment options. *J Sex Med* 2012; **9**: 5-13; quiz 14-5 [PMID: 22151953 DOI: 10.1111/j.1743-6109.2011.02566.x]

44 **Pruthi S**, Simon JA, Early AP. Current overview of the management of urogenital atrophy in women with breast cancer. *Breast J* 2011; **17**: 403-408 [PMID: 21645165 DOI: 10.1111/j.1524-4741.2011.01089.x]

45 **Sinha A**, Ewies AA. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. *Climacteric* 2013; **16**: 305-312 [PMID: 23215675 DOI: 10.3109/13697137.2012.756466]

46 **Management of symptomatic vulvovaginal atrophy**: 2013 position statement of The North American Menopause Society. *Menopause* 2013; **20**: 888-902; quiz 903-4 [PMID: 23985562 DOI: 10.1097/GME.0b013e3182a122c2]

47 **Capobianco G**, Donolo E, Borghero G, Dessole F, Cherchi PL, Dessole S. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. *Arch Gynecol Obstet* 2012; **285**: 397-403 [PMID: 21706345 DOI: 10.1007/s00404-011-1955-1]

48 **Cuzick J**, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. *Lancet Oncol* 2010; **11**: 1135-1141 [PMID: 21087898 DOI: 10.1016/s1470-2045(10)70257-6]

49 **Moegele M**, Buchholz S, Seitz S, Ortmann O. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. *Arch Gynecol Obstet* 2012; **285**: 1397-1402 [PMID: 22212649 DOI: 10.1007/s00404-011-2181-6]

50 **Witherby S**, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, Wood M, Muss H. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. *Oncologist* 2011; **16**: 424-431 [PMID: 21385795 DOI: 10.1634/theoncologist.2010-0435]

51 **Labrie F**, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Martel C, Balser J. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. *Gynecol Endocrinol* 2010; **26**: 524-532 [PMID: 20459349 DOI: 10.3109/09513590903511547]

52 **Buckner J.** ClinicalTrials.gov Identifier: NCT01376349. Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms, cited 12/17/2013. Available from: URL: http: //clinicaltrials.gov/show/NCT01376349

53 **Wurz GT**, Soe LH, Degregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer. *Maturitas* 2013; Epub ahead of print [PMID: 23332519 DOI: 10.1016/j.maturitas.2012.12.002]

54 **Howlader N**, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2010, based on November 2012 SEER data submission, posted to the SEER web site, April 2013, cited Available from: URL: http: //seer.cancer.gov/csr/1975\_2010/

55 **Su HI**. Measuring ovarian function in young cancer survivors. *Minerva Endocrinol* 2010; **35**: 259-270 [PMID: 21178920]

56 **Hortobagyi GN**, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. *NCI Monogr* 1986: 105-109 [PMID: 3534581]

57 **Loren AW**, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 2013; **31**: 2500-2510 [PMID: 23715580 DOI: 10.1200/jco.2013.49.2678]

58 **de Bree E**, Makrigiannakis A, Askoxylakis J, Melissas J, Tsiftsis DD. Pregnancy after breast cancer. A comprehensive review. *J Surg Oncol* 2010; **101**: 534-542 [PMID: 20401921 DOI: 10.1002/jso.21514]

59 **Azim HA**, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart MJ, Peccatori FA. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. *J Clin Oncol* 2013; **31**: 73-79 [PMID: 23169515 DOI: 10.1200/jco.2012.44.2285]

60 **Valachis A**, Tsali L, Pesce LL, Polyzos NP, Dimitriadis C, Tsalis K, Mauri D. Safety of pregnancy after primary breast carcinoma in young women: a meta-analysis to overcome bias of healthy mother effect studies. *Obstet Gynecol Surv* 2010; **65**: 786-793 [PMID: 21411023 DOI: 10.1097/OGX.0b013e31821285bf]

61 **Leal SC**, Stuart SR, Carvalho Hde A. Breast irradiation and lactation: a review. *Expert Rev Anticancer Ther* 2013; **13**: 159-164 [PMID: 23406557 DOI: 10.1586/era.12.178]

62 **Marchbanks PA**, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, Norman SA, Wingo PA, Burkman RT, Berlin JA, Simon MS, Spirtas R, Weiss LK. Oral contraceptives and the risk of breast cancer. *N Engl J Med* 2002; **346**: 2025-2032 [PMID: 12087137 DOI: 10.1056/NEJMoa013202]

63 **Casey PM**, Cerhan JR, Pruthi S. Oral contraceptive use and risk of breast cancer. *Mayo Clin Proc* 2008; **83**: 86-90; quiz 90-1 [PMID: 18174010]

64 **Collaborative Group on Hormonal Factors in Breast Cancer.** Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. *Lancet* 1996; **347**: 1713-1727 [PMID: 8656904]

65 **Association of Reproductive Health Professionals.** Non-hormonal Contraceptive Methods. Section 1. Highly Effective Non-hormonal Methods Available in the US Male Sterilization, published July 2013, cited 12/17/2013. Available from: URL: http: //www.arhp.org/Publications-and-Resources/Quick-Reference-Guide-for-Clinicians/Non-hormonal-Choosing/male-sterilization

66 **Association of Reproductive Health Professionals.** Non-hormonal Contraceptive Methods. Female Sterilization, published July 2013, cited 12/17/2013. Available from: URL: http: //www.arhp.org/Publications-and-Resources/Quick-Reference-Guide-for-Clinicians/Non-hormonal-Choosing/female-sterilization

67 **Conceptus Incorporated.** Essure package insert, cited 12/16/2013. Available from: URL: http: //www.essuremd.com/App\_Themes/BaseTheme/PDFs/Link Essure IFU.pdf

68 **Centers for Disease Control and Prevention (CDC).** United States Medical Eligibility Criteria (US MEC) for Contraceptive Use, 2010, cited 12/16/2013. Available from: URL: http: //www.cdc.gov/reproductivehealth/unintendedpregnancy/usmec.htm

69 **Trussell J**. Contraceptive efficacy. In Contraceptive Technology. 18th edition. Edited by Hatcher R, Trussell J, Stewart F, Nelson A, Cates W, Guest F, Kowal D. New York, NY: Ardent Media, Incorporated; 2007

70 **Teva Women’s Health Inc.** ParaGard® T 380A Intrauterine Copper Contraceptive package insert, updated June 2013, cited 12/16/2013. Available from: URL: http: //www.paragard.com/images/ParaGard\_info.pdf

71 **Bayer HealthCare Pharmaceuticals Inc**. Mirena (levonorgestrel-releasing intrauterine system) package insert, updated February 2013, cited 12/16/2013. Available from: URL: http: //labeling.bayerhealthcare.com/html/products/pi/Mirena\_PI.pdf

72 **Bayer HealthCare Pharmaceuticals Inc.** SKYLA (levonorgestrel-releasing intrauterine system) package insert, updated September 2013, cited 12/16/2013. Available from: URL: http: //labeling.bayerhealthcare.com/html/products/pi/Skyla\_PI.pdf

73 **Dinger J**, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. *Contraception* 2011; **83**: 211-217 [PMID: 21310281 DOI: 10.1016/j.contraception.2010.11.009]

74 **Trinh XB**, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. *Fertil Steril* 2008; **90**: 17-22 [PMID: 17706209 DOI: 10.1016/j.fertnstert.2007.05.033]

75 **Milsom I**. The levonorgestrel-releasing intrauterine system as an alternative to hysterectomy in peri-menopausal women. *Contraception* 2007; **75**: S152-S154 [PMID: 17531608 DOI: 10.1016/j.contraception.2007.01.003]

76 **Lukes AS**, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, Richter HE, Eder SE, Attia GR, Patrick DL, Rubin A, Shangold GA. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. *Obstet Gynecol* 2010; **116**: 865-875 [PMID: 20859150 DOI: 10.1097/AOG.0b013e3181f20177]

77 **Roy SN**, Bhattacharya S. Benefits and risks of pharmacological agents used for the treatment of menorrhagia. *Drug Saf* 2004; **27**: 75-90 [PMID: 14717620]

78 **Merck & Co. Inc.** NEXPLANON® (etonogestrel implant) package insert, updated September 2013, cited 12/16/2013. Available from: URL: http: //www.merck.com/product/usa/pi\_circulars/n/nexplanon/nexplanon\_pi.pdf

79 **Blumenfeld Z**. Chemotherapy and fertility. *Best Pract Res Clin Obstet Gynaecol* 2012; **26**: 379-390 [PMID: 22281514 DOI: 10.1016/j.bpobgyn.2011.11.008]

80 **Di Cosimo S**, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, Fabi A, Gelibter A, Ciccarese M, Giannarelli D, Mandalà M, Milella M, Ruggeri EM, Cognetti F. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. *Ann Oncol* 2004; **15**: 1065-1071 [PMID: 15205200 DOI: 10.1093/annonc/mdh266]

81 **World Health Organization**. Medical Eligibility Criteria for Contraceptive Use, cited 12/16/2013. Available from: URL: http: //whqlibdoc.who.int/publications/2004/9241562668.pdf

82 **Zhou L**, Xiao B. Emergency contraception with Multiload Cu-375 SL IUD: a multicenter clinical trial. *Contraception* 2001; **64**: 107-112 [PMID: 11704087]

83 **Watson Pharma Inc.** ELLA (ulipristal acetate tablet) package insert, updated April 2012, cited 12/17/2013. Available from: URL: http: //pi.actavis.com/data\_stream.asp?product\_group=1699&p=pi&language=E

84 **Barr Pharmaceuticals Inc.** Plan B One-Step (levonorgestrel) tablet package insert, updated August 2009, cited 12/17/2013. Available from: URL: http: //www.planbonestep.com/pdf/PlanBOneStepFullProductInformation.pdf

85 Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation. *Lancet* 1998; **352**: 428-433 [PMID: 9708750]

86 **Glasier AF**, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. *Lancet* 2010; **375**: 555-562 [PMID: 20116841 DOI: 10.1016/s0140-6736(10)60101-8]

87 **Reid DM**. Prevention of osteoporosis after breast cancer. *Maturitas* 2009; **64**: 4-8 [PMID: 19709826 DOI: 10.1016/j.maturitas.2009.07.008]

88 **Abdel-Razeq H**, Awidi A. Bone health in breast cancer survivors. *J Cancer Res Ther* 2011; **7**: 256-263 [PMID: 22044804 DOI: 10.4103/0973-1482.87006]

89 **Aapro MS**, Coleman RE. Bone health management in patients with breast cancer: current standards and emerging strategies. *Breast* 2012; **21**: 8-19 [PMID: 21958673 DOI: 10.1016/j.breast.2011.08.138]

90 **Peppone LJ**, Mustian KM, Rosier RN, Carroll JK, Purnell JQ, Janelsins MC, Morrow GR, Mohile SG. Bone health issues in breast cancer survivors: a Medicare Current Beneficiary Survey (MCBS) study. *Support Care Cancer* 2014; **22**: 245-251 [PMID: 24043289 DOI: 10.1007/s00520-013-1967-4]

91 **Michaud LB**, Goodin S. Cancer-treatment-induced bone loss, part 1. *Am J Health Syst Pharm* 2006; **63**: 419-430 [PMID: 16484516 DOI: 10.2146/ajhp050045.p1]

92 **Reid DM**, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. *Cancer Treat Rev* 2008; **34 Suppl 1**: S3-18 [PMID: 18515009 DOI: 10.1016/j.ctrv.2008.03.007]

93 **Coates AS**, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. *J Clin Oncol* 2007; **25**: 486-492 [PMID: 17200148 DOI: 10.1200/jco.2006.08.8617]

94 **Coombes RC**, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. *Lancet* 2007; **369**: 559-570 [PMID: 17307102 DOI: 10.1016/s0140-6736(07)60200-1]

95 **Coleman RE**, Body JJ, Gralow JR, Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. *Cancer Treat Rev* 2008; **34 Suppl 1**: S31-S42 [PMID: 18486346 DOI: 10.1016/j.ctrv.2008.03.005]

96 **National Osteoporosis Foundation (NOF)**. 2013 Clinician's Guide to Prevention and Treatment of Osteoporosis, cited 12/2/2013. Available from: URL: http: //nof.org/files/nof/public/content/file/950/upload/523.pdf

97 **Hillner BE**, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. *J Clin Oncol* 2003; **21**: 4042-4057 [PMID: 12963702 DOI: 10.1200/jco.2003.08.017]

**P-Reviewers:** Editorial O, Petmitr S **S-Editor:** Ji FF **L-Editor: E-Editor:**

Lifestyle advice
Begin calcium and vitamin D

Lifestyle advice
Begin calcium and vitamin D

Begin therapy

Alendronate or

Risedronate or
Zoledronic acid or

Raloxifene

Lifestyle advice
Begin calcium and vitamin D

Reassure

Lifestyle advice
Begin calcium and vitamin D

Monitor annually for risk status
by history

Screening for BMD Not Recommended

Repeat BMD, Annually

Repeat BMD, Annually

Repeat BMD, Annually

T-score -1 and -2.5

T-score -2.5 or lower

T-score >-1

Screening for BMD Recommended
DXA of Hip ± Spine

High Risk

Low Risk

Breast Cancer Patient
Screened for Osteoporosis Risk

High Risk

* All women age >65 years
* All women age 60-64 years with
	+ Family history
	+ Body weight <70 kg
	+ Prior non-traumatic fracture
	+ Other risk factors

Postmenopausal women of any age receiving aromatase inhibitors

* Premenopausal women with therapy-associated premature menopause

**Figure 1 Recommended management strategy for patients with diagnosed nonmetastatic breast cancer[97].** This management strategy is largely based on influence from results in non-breast cancer populations. BMD: Bone mass density; DEXA: Dual energy x-ray absorptiometry bone scan. Reprinted with permission. © (2003) American Society of Clinical Oncology. All rights reserved.

Oophorectomy, treatment-induced menopause or ovarian suppression therapy planned

Measure BMD by axial DXA (spine and hip) within 3 months of commencing treatment

T-score
<-1.0 or known vertebral fracture

Without AI

Assess for secondary osteoporosisa

Lifestyle advice
Calcium + vitamin D supplementation if
clinically deficient

Lifestyle advice
Reassure patient
No further assessment unless clinically indicated

Treat with bisphosphonatesb at osteoporosis doses and calcium + vitamin D supplementationc

Repeat axial BMD after 24 months of therapy

Repeat axial DXA after
24 months and/or monitor
if desired with biochemical markersd after 6 months

Annual rate of bone loss of >4% at lumbar spine or total hip and/or
T-score <-2.0

Yes

No

High Risk

Medium Risk

Low Risk

T-score
<-2.0 or known vertebral fracture

With AI

Without AI

T-score
>-1.0

T-score
<-1.0 but
>-2.0

With AI

Without AI

T-scores >-1.0

With or without aromatase inhibitor (AI) use

**Figure 2 Adjuvant treatment associated with ovarian suppression/failure with or without concomitant aromatase inhibitor use in women who experience premature menopause[92].** aErythrocyte sedimentation rate, full blood count, bone and liver function (calcium phosphate, alkaline phosphatase, albumin, AST/γGT), serum creatinine, endomysial antibodies, serum thyroid stimulating hormone; bAlendronate 70 mg per week, risedronate 35 mg per week, ibandronate (150 mg po monthly or 3 mg *iv* 3-monthly), zoledronic acid 4 mg iv 6-monthly; cTo be given as ≥ 1 g of calcium + ≥ 800 IU of vitamin D; dBiochemical markers such as serum C-terminal telopeptide of type I collagen or urinary N-telopeptide of type I collagen.Reprinted with permission. © (2008) Elsevier.

Commencing aromatase inhibitor therapy

Measure BMD by axial DXA (spine and hip) within 3-6 months

All other patients

Age ≥75 years
and ≥1 clinical risk factorsa

Low T-score <-2.0 or known vertebral fracture

Low T-score <-1.0 but >-2.0

Both T-scores >-1.0

Assess for secondary osteoporosisb
Calcium + vitamin D supplementation if
clinically deficient

Lifestyle advice
Calcium + vitamin D supplementation if
clinically deficient

Lifestyle advice
Reassure patient
No further assessment unless clinically indicated

Treat with bisphosphonatesc at osteoporosis doses and calcium + vitamin D supplementationd

Repeat axial BMD, if available, after 24 months of therapy

Repeat axial DXA after
24 months and/or monitor
if desired with biochemical markerse after 6 months

Annual rate of bone loss of >4% at lumbar spine or total hip and/or T-score <-2.0

Yes

No

High Risk

Medium Risk

Low Risk

**Figure 3 Postmenopausal adjuvant treatment with aromatase inhibitors[92].** aPrevious low-trauma fracture after age 50, parental history of hip fracture, alcohol intake of ≥ 4 units/day, diseases associated with secondary osteoporosis, prior corticosteroids for > 6 months, low BMI (< 22);bErythrocyte sedimentation rate, full blood count, bone and liver function (calcium phosphate, alkaline phosphatase, albumin, AST/γGT), serum creatinine, endomysial antibodies, serum thyroid stimulating hormone; cAlendronate 70 mg per week, risedronate 35 mg per week, ibandronate (150 mg po monthly or 3 mg iv 3-monthly), zoledronic acid 4 mg *iv* 6-monthly; dTo be given as ≥ 1 g of calcium + ≥ 800 IU of vitamin D;eBiochemical markers such as serum C-terminal telopeptide of type I collagen or urinary N-telopeptide of type I collagen.Reprinted with permission. © (2008) Elsevier.